National Institute of Allergy and Infectious Diseases (NIAID)
This Phase I/II clinical trial will study the safety and potential benefits of gene therapy for up to 35 people aged 2 to 50 with X-linked severe combined immunodeficiency (XSCID), a rare genetic condition that makes it difficult to fight infections. The study is for patients with XSCID who have serious immune system problems, including those who continue to experience serious immune complications after a previous stem cell transplant, and who do not have a suitably matched sibling donor. Treatment uses the patient s own blood-forming stem cells, which are collected from the bloodstream. In a laboratory, a specially designed delivery system called a lentiviral vector adds a working copy of the affected gene to these cells to help them produce functioning immune cells. Before receiving the modified cells, patients will receive a reduced dose of busulfan, a chemotherapy medicine that makes room in the bone marrow for the treated cells. The dose may be further adjusted according to the study protocol, including for patients with significant organ damage. Alemtuzumab (Campath) may also be given when clinically indicated, including to address certain immune problems involving donor T cells from a previous transplant. The modified stem cells will then be returned through a single infusion into a vein. Researchers will monitor side effects, how well the modified cells survive and produce immune cells, and whether patients develop stronger immune function and better health. The main assessment will occur two years after treatment, with follow-up visits continuing through year five. A separate long-term follow-up study will monitor patients through year 15 for lasting benefits and delayed side effects, including cancer. This treatment is experimental, and its benefits and risks are not yet fully known....
This is a non-randomized clinical trial of gene transfer using a self-inactivating, insulated, lentiviral gene transfer vector to treat 35 patients with X-linked severe combined immunodeficiency (XSCID, also called SCID-X1) who are between 2 and 50 years of age; who do not have a tissue matched sibling who can donate bone marrow for a transplant; who may have failed to obtain sufficient benefit from a previous half-tissue matched bone marrow transplant; and who have clinically significant impairment of immunity. A patient's own precursor cells (also called blood stem cells) that give rise in t…
* INCLUSION CRITERIA: * A proven mutation in the common gamma chain gene as defined by direct sequencing of patient DNA * No available HLA matched sibling donor as determined before enrollment (HLA typing will be performed prior to enrollment) * Must be between 2 and 50 years of age and weigh 10 kg * If previously transplanted, must be 18 months post-HSCT * Expected survival of at least 120 days. * Participants of reproductive potential must agree to consistently use highly effective contraception throughout study participation and for at least 2 years post-treatment. Acceptable forms of contr…
May be administered subcutaneously Days -21 through Day -19 in patients who demonstrate evidence of donor T cell dysregulation
Mucositis prophylaxis commenced- Infusion of keratinocyte growth factor (palifermin) at 60 mcg/kg/day before (Days -6 to Day -4) administration of busulfan and (Days +1 to +3) post-busulfan administration
3mg/kg per day with drug levels obtained on Day -3. Busulfan dose on day -2 will be adjusted (if busulfan AUC result is available) to achieve targeted busulfan AUC 4500 min\*umol/L/day. Dose reduction to a total dose of 4mg/kg (target AUC 6000 min\*umol/L/day) may be offered to patients with significant organ damage
Transduced cell product administered intravenously over approximately 30 minutes by authorized licensed personnel consistent with NIH Clinical Center Department of Transfusion Medicine's standard operating procedures for cellular products.